Src-family kinases emerge as potential targets in diabetic nerve damage

A review identifies Src-family kinases as possible links between high blood sugar, inflammation, oxidative stress and nerve pain, while stressing that evidence for treating diabetic neuropathy remains preliminary.

Diabetic peripheral neuropathy remains one of the most damaging long-term complications of diabetes, causing numbness, pain, loss of sensation and impaired nerve function, and in severe cases contributing to foot ulceration, infection and amputation. A review in Dove Press says the condition affects a substantial share of people with diabetes and becomes more common as disease duration lengthens, underscoring the scale of the problem for health systems already managing rising diabetes rates. Large observational studies reinforce that picture: a nationwide Chinese survey found painful neuropathy in 57.2% of patients with type 2 diabetes and neuropathy, while international data from the INTERPRET-DD study reported a DPN prevalence of 26.71% among people with type 2 diabetes across 14 countries.

The review argues that current treatment remains limited, largely centred on glucose control and symptom relief, rather than on therapies that can halt or reverse nerve damage. That therapeutic gap has prompted growing interest in signalling pathways that sit upstream of inflammation, oxidative stress and neuronal injury. One such pathway involves Src-family protein tyrosine kinases, a group of enzymes that help transmit signals inside cells and may connect metabolic stress to the tissue damage seen in diabetic nerve disease.

Src-family kinases are already known to influence cell growth, survival, movement and inflammation, and the review says they are increasingly viewed as key nodes in nervous-system signalling. In healthy tissue, they help regulate neuronal development, synaptic plasticity and axonal growth. Under stress, however, their activity can become excessive. The review says hyperglycaemia, oxidative stress and inflammatory signals can all encourage abnormal Src-family activation, which may then amplify the pathways that drive diabetic neuropathy and diabetic nerve pain.

A major theme in the review is neuronal sensitisation, the process by which pain pathways become overactive. The authors say Src-family kinases may contribute to both central sensitisation, in the spinal cord, and peripheral sensitisation, in sensory nerves and dorsal root ganglia. They cite evidence linking Fyn to NR2B, a subunit of the NMDA receptor involved in pain transmission, and describe a separate pathway in which PTP1B promotes Src activation and strengthens spinal pain signalling. They also note that Src can regulate ion channels such as TRPV1 and TRPV4, which are associated with heightened sensitivity to heat, touch and mechanical stimulation.

The review also points to the likely role of Src-family kinases in neuroinflammation and oxidative stress, two processes widely implicated in diabetic nerve injury. Microglia and astrocytes, the immune-support cells of the nervous system, can release inflammatory mediators that intensify pain and neuronal damage. The authors say Src and Fyn may help drive these responses, while related pathways involving NF-κB, MAPK, iNOS and NOX2 may further increase reactive oxygen and nitrogen species. In other words, the kinases may sit at the intersection of inflammation and oxidative injury rather than acting through a single mechanism alone.

Although the therapeutic evidence remains early, the review highlights several possible routes forward. Classic Src-family inhibitors such as PP1 and PP2 have shown pain-relieving effects in animal models, and the authors say more clinically advanced compounds, including dasatinib and saracatinib, warrant further study. They also point to strategies that interfere with downstream signalling complexes, rather than shutting down the kinases completely, as a way to preserve normal physiological functions while blocking pathological activation. Traditional Chinese medicine and electroacupuncture are discussed as additional approaches that may influence Src-related pathways, although the review stresses that the evidence base is still incomplete.

The broader implication is that diabetic peripheral neuropathy is unlikely to yield to a single-target solution. The review argues that Src-family kinases may help link hyperglycaemia to neuronal sensitisation, glial activation, inflammation and oxidative stress, making them attractive candidates for future research. But it also cautions that much of the existing evidence comes from general neuropathic pain or other neurological disease models rather than direct human data in diabetic neuropathy. For now, the message is less that Src-family kinases have become a proven treatment target than that they offer a promising framework for understanding how metabolic disease turns into chronic nerve damage.